• 1. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824839.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004; 50: 15031510.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3. Moe GW. B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006; 21: 208214.

  • 4. Seilhamer JJ, Arfsten A, Miller JA, et al. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun 1989; 165: 650658.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5. Cortés R, Portoles M, Rosello-Lleti E, et al. Impact of glomerular filtration rate on urinary BNP and NT-proBNP levels in heart failure. Peptides 2012; 33: 354358.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6. Thomas CJ, Woods RL. Haemodynamic action of B-type natriuretic peptide substantially outlasts its plasma half-life in conscious dogs. Clin Exp Pharmacol Physiol 2003; 30: 369375.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7. Kimura K, Yamaguchi Y, Horii M, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 2007; 63: 699702.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000; 36: 355359.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9. Mueller T, Gegenhuber A, Dieplinger B, et al. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004; 42: 942944.

    • Search Google Scholar
    • Export Citation
  • 10. Asano K, Masuda K, Okumura M, et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. J Vet Med Sci 1999; 61: 523529.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11. Takemura N, Toda N, Miyagawa Y, et al. Evaluation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations in dogs with mitral valve insufficiency. J Vet Med Sci 2009; 71: 925929.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12. Boswood A, Dukes-McEwan J, Loureiro J, et al. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract 2008; 49: 2632.

    • Search Google Scholar
    • Export Citation
  • 13. Oyama MA, Fox PR, Rush JE, et al. Clinical utility of serum N-terminal pro–B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008; 232: 14961503.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. MacDonald KA, Kittleson MD, Munro C, et al. Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. J Vet Intern Med 2003; 17: 172177.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15. Ettinger SJ, Farace G, Forney SD, et al. Evaluation of plasma N-terminal pro–B-type natriuretic peptide concentrations in dogs with and without cardiac disease. J Am Vet Med Assoc 2012; 240: 171180.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16. Connolly DJ. Natriuretic peptides: the feline experience. Vet Clin North Am Small Anim Pract 2010; 40: 559570.

  • 17. Connolly DJ, Soares Magalhaes RJ, Fuentes VL, et al. Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J Vet Cardiol 2009; 11(suppl 1): S41S50.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18. Wess G, Daisenberger P, Mahling M, et al. Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats. Vet Clin Pathol 2011; 40: 237244.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19. Wess G, Butz V, Mahling M, et al. Evaluation of N-terminal pro–B-type natriuretic peptide as a diagnostic marker of various stages of cardiomyopathy in Doberman Pinschers. Am J Vet Res 2011; 72: 642649.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20. Fox PR, Oyama MA, Reynolds CA, et al. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-pro BNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J Vet Cardiol 2009; 11(suppl 1): S51S61.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21. Fox PR, Rush JE, Reynolds CA, et al. Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats. J Vet Intern Med 2011; 25: 10101016.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22. Ogawa K, Oida A, Sugimura H, et al. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: comparison of electrocardiography, chest radiography and echocardiography. Circ J 2002; 66: 122126.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23. Connolly DJ, Magalhaes RJ, Syme HM, et al. Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med 2008; 22: 96105.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24. Singletary GE, Morris NA, O'Sullivan ML, et al. Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers. J Vet Intern Med 2012; 26: 13301336.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25. Hsu A, Kittleson MD & Paling A. Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. J Vet Cardiol 2009; 11(suppl 1): S63S70.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26. Oyama MA, Rush JE, Rozanski EA, et al. Assessment of serum N-terminal pro–B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs. J Am Vet Med Assoc 2009; 235: 13191325.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27. Fagan TJ. Letter: nomogram for Bayes theorem. N Engl J Med 1975; 293:257.

  • 28. Wieshammer S, Dreyhaupt J & Basler B. Elevated levels of N-terminal pro-brain natriuretic peptide in patients with chronic dyspnea and moderate renal dysfunction: decreased clearance or increased cardiac stress? Cardiorenal Med 2011; 1: 156163.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29. Balik M, Jabor A, Otahal M, et al. Impact of acute renal failure on the relationship between N-terminal pro-B-type natriuretic peptide and hemodynamic parameters. Blood Purif 2011; 31: 4754.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30. Schmidt MK, Reynolds CA, Estrada AH, et al. Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: a pilot study. J Vet Cardiol 2009; 11(suppl 1): S81S86.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31. Lalor SM, Connolly DJ, Elliott J, et al. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. J Vet Cardiol 2009; 11(suppl 1): S71S79.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32. Chetboul V, Daste T, Gouni V, et al. Renal resistive index in 55 dogs with degenerative mitral valve disease. J Vet Intern Med 2012; 26: 101108.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33. Yamashita T, Seino Y, Ogawa A, et al. N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratification in patients admitted for cardiac emergency. J Cardiol 2010; 55: 377383.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34. Palladini G, Foli A, Milani P, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012; 87: 465471.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35. Liu SK, Peterson ME, Fox PR. Hypertropic cardiomyopathy and hyperthyroidism in the cat. J Am Vet Med Assoc 1984; 185: 5257.

  • 36. Menaut P, Connolly DJ, Volk A, et al. Circulating natriuretic peptide concentrations in hyperthyroid cats. J Small Anim Pract 2012; 53: 673678.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37. Liang F, Webb P, Marimuthu A, et al. Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 2003; 278: 1507315083.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38. Kellihan HB, Mackie BA, Stepien RL. NT-proBNP, NT-proANP and cTnI concentrations in dogs with pre-capillary pulmonary hypertension. J Vet Cardiol 2011; 13: 171182.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39. Collins SA, Patteson MW, Connolly DJ, et al. Effects of sample handling on serum N-terminal proB-type natriuretic peptide concentration in normal dogs and dogs with heart disease. J Vet Cardiol 2010; 12: 4148.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40. Connolly DJ, Hezzell MJ, Fuentes VL, et al. The effect of protease inhibition on the temporal stability of NT-proBNP in feline plasma at room temperature. J Vet Cardiol 2011; 13: 1319.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41. Schellenberg S, Grenacher B, Kaufmann K, et al. Analytical validation of various immunoassays for the quantification of cardiovascular peptides in dogs. Vet J 2008; 178: 8590.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42. Kellihan HB, Oyama MA, Reynolds CA, et al. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. J Vet Cardiol 2009; 11(suppl 1): S93S97.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43. Singletary GE, Rush JE, Fox PR, et al. Effect of NT-pro-BNP assay on accuracy and confidence of general practitioners in diagnosing heart failure or respiratory disease in cats with respiratory signs. J Vet Intern Med 2012; 26: 542546.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161167.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948954.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46. Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115: 31033110.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47. Tang WH, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem 2008; 41: 210221.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48. Fine DM, Declue AE, Reinero CR. Evaluation of circulating amino terminal-pro–B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. J Am Vet Med Assoc 2008; 232: 16741679.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49. Steinhart B, Thorpe KE, Bayoumi AM, et al. Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol 2009; 54: 15151521.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416422.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51. Fox PR. Spontaneous animal models. In: Marcus FI, Nava A, eds. Arrhythmogenic right ventricular cardiomyopathy/dysplasia recent advances. Milan: Italiana Springer, 2007; 6970.

    • Search Google Scholar
    • Export Citation
  • 52. Charron P, Forissier JF, Amara ME, et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int J Cardiol 2003; 90: 3338.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 53. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 18071816.

    • Search Google Scholar
    • Export Citation
  • 54. Paige CF, Abbott JA, Elvinger F, et al. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc 2009; 234: 13981403.

  • 55. Côté E, Manning AM, Emerson D, et al. Assessment of the prevalence of heart murmurs in overtly healthy cats. J Am Vet Med Assoc 2004; 225: 384388.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 56. Wagner T, Fuentes VL, Payne JR, et al. Comparison of auscultatory and echocardiographic findings in healthy adult cats. J Vet Cardiol 2010; 12: 171182.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 57. Dirven MJ, Cornelissen JM, Barendse MA, et al. Cause of heart murmurs in 57 apparently healthy cats. Tijdschr Diergeneeskd 2010; 135: 840847.

    • Search Google Scholar
    • Export Citation
  • 58. Smith S & Dukes-McEwan J. Clinical signs and left atrial size in cats with cardiovascular disease in general practice. J Small Anim Pract 2012; 53: 2733.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59. Schober KE, Maerz I, Ludewig E, et al. Diagnostic accuracy of electrocardiography and thoracic radiography in the assessment of left atrial size in cats: comparison with transthoracic 2-dimensional echocardiography. J Vet Intern Med 2007; 21: 709718.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 60. Tominaga Y, Miyagawa Y, Toda N, et al. The diagnostic significance of the plasma N-terminal pro-B-type natriuretic peptide concentration in asymptomatic cats with cardiac enlargement. J Vet Med Sci 2011; 73: 971975.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 61. Singh MK, Cocchiaro MF, Kittleson MD. NT-proBNP measurement fails to reliably identify subclinical hypertrophic cardiomyopathy in Maine Coon cats. J Feline Med Surg 2010; 12: 942947.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62. Hazlett MJ, Maxie MG, Allen DG, et al. A retrospective study of heart disease in Doberman Pinscher dogs. Can Vet J 1983; 24: 205210.

  • 63. Wess G, Schulze A, Butz V, et al. Prevalence of dilated cardiomyopathy in Doberman Pinschers in various age groups. J Vet Intern Med 2010; 24: 533538.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 64. Calvert CA, Meurs KM. Doberman Pinscher occult cardiomyopathy. In: Bonagura JD, Kirk RW, eds. Current veterinary therapy XIII: small animal practice. Philadelphia: WB Saunders, 2000; 75660.

    • Search Google Scholar
    • Export Citation
  • 65. Tidholm A, Haggstrom J, Borgarelli M, et al. Canine idiopathic dilated cardiomyopathy. Part I: aetiology, clinical characteristics, epidemiology and pathology. Vet J 2001; 162: 92107.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66. Basso C, Fox PR, Meurs KM, et al. Arrhythmogenic right ventricular cardiomyopathy causing sudden cardiac death in boxer dogs: a new animal model of human disease. Circulation 2004; 109: 11801185.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 67. Calvert CA, Jacobs J, Pickus CW, et al. Results of ambulatory electrocardiography in overtly healthy Doberman Pinschers with echocardiographic abnormalities. J Am Vet Med Assoc 2000; 217: 13281332.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68. O'Grady MR, O'Sullivan ML. Dilated cardiomyopathy: an update. Vet Clin North Am Small Anim Pract 2004; 34: 11871207.

  • 69. Wess G, Maurer J, Simak J, et al. Use of Simpson's method of disc to detect early echocardiographic changes in Doberman Pinschers with dilated cardiomyopathy. J Vet Intern Med 2010; 24: 10691076.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 70. Meurs KM, Lahmers S, Keene BW, et al. A splice site mutation in a gene encoding for PDK4, a mitochondrial protein, is associated with the development of dilated cardiomyopathy in the Doberman Pinscher. Hum Genet 2012; 131: 13191325.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 71. Baumwart RD, Meurs KM. Assessment of plasma brain natriuretic peptide concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res 2005; 66: 20862089.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 72. Detweiler DK, Patterson DF. The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 1965; 127: 481516.

  • 73. Buchanan JW. Chronic valvular disease (endocardiosis) in dogs. Adv Vet Sci Comp Med 1977; 21: 75106.

  • 74. Whitney JC. Observations on the effect of age on the severity of heart valve lesions in the dog. J Small Anim Pract 1974; 15: 511522.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75. Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 2008; 22: 120128.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 76. Lord PF, Hansson K, Carnabuci C, et al. Radiographic heart size and its rate of increase as tests for onset of congestive heart failure in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med 2011; 25: 13121319.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 77. Tarnow I, Olsen LH, Kvart C, et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J 2009; 180: 195201.

  • 78. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 2009; 54: 10991106.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 79. Chetboul V, Serres F, Tissier R, et al. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med 2009; 23: 984994.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 80. Reynolds CA, Brown DC, Rush JE, et al. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study. J Vet Cardiol 2012; 14: 193202.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 81. Schober KE, Hart TM, Stern JA, et al. Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 2011; 239: 468479.

    • Search Google Scholar
    • Export Citation
  • 82. Noszczyk-Nowak A. NT-pro-BNP and troponin I as predictors of mortality in dogs with heart failure. Pol J Vet Sci 2011; 14: 551556.

  • 83. Wolf J, Gerlach N, Weber K, et al. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease. J Vet Cardiol 2012; 14: 399408.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 84. Hezzell MJ, Boswood A, Chang YM, et al. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease. J Vet Intern Med 2012; 26: 302311.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 85. Moonarmart W, Boswood A, Luis Fuentes V, et al. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 2010; 51: 8496.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 86. Serres F, Pouchelon J-L, Poujol L, et al. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission. J Vet Cardiol 2009; 11: 103121.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 87. Greco DS, Biller B, Van Liew CH. Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J 2003; 44: 293297.

    • Search Google Scholar
    • Export Citation
  • 88. Bayés-Genís A, Lopez L, Zapico E, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail 2005; 11:S3S8.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 89. Januzzi JL Jr. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis 2012; 105: 4050.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 90. Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010; 170: 507514.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 91. Felker GM, Hasselblad V, Hernandez AF, et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009; 158: 422430.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 92. Vavuranakis M, Kariori MG, Kalogeras KI, et al. Biomarkers as a guide of medical treatment in cardiovascular diseases. Curr Med Chem 2012; 19: 24852496.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 93. Karlström P, Alehagen U, Boman K, et al. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 2011; 13: 10961103.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 94. Shah MR, Califf RM, Nohria A, et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 2011; 17: 613621.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 95. Tentzeris I, Jarai R, Farhan S, et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail 2011; 13: 726733.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 96. Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 2013; 102: 103110.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 97. Bayes-Genis A, Pascual-Figal D, Januzzi JL, et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol 2010; 63: 11711178.

    • Search Google Scholar
    • Export Citation

Advertisement

Clinical usefulness of an assay for measurement of circulating N-terminal pro-B-type natriuretic peptide concentration in dogs and cats with heart disease

Mark A. OyamaDepartment of Clinical Studies-Philadelphia, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104

Search for other papers by Mark A. Oyama in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Adrian BoswoodDepartment of Clinical Sciences, Royal Veterinary College, University of London, North Mymms, Hertfordshire, AL9 7TA England

Search for other papers by Adrian Boswood in
Current site
Google Scholar
PubMed
Close
 MA, vetMB
,
David J. ConnollyDepartment of Clinical Sciences, Royal Veterinary College, University of London, North Mymms, Hertfordshire, AL9 7TA England

Search for other papers by David J. Connolly in
Current site
Google Scholar
PubMed
Close
 BVetMed, PhD
,
Stephen J. EttingerVCA California Animal Hospital Veterinary Specialty Group, 1736 S Sepulveda Blvd, Los Angeles, CA 90025

Search for other papers by Stephen J. Ettinger in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Philip R. FoxAnimal Medical Center, 510 E 62nd St, New York, NY 10065

Search for other papers by Philip R. Fox in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVIM, DACVECC
,
Sonya G. GordonDepartment of Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843

Search for other papers by Sonya G. Gordon in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
John E. RushDepartment of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536

Search for other papers by John E. Rush in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVIM, DACVECC
,
D. David SissonDepartment of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331

Search for other papers by D. David Sisson in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Rebecca L. StepienDepartment of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706

Search for other papers by Rebecca L. Stepien in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVIM
,
Gerhard WessClinic of Small Animal Medicine, Ludwig-Maximilians Universität, Munich, Germany 80539

Search for other papers by Gerhard Wess in
Current site
Google Scholar
PubMed
Close
 Dr Med Vet, Dr med vet habil, DACVIM
, and
Faiez ZannadDepartment of Cardiology, Nancy University, Université de Lorraine, Nancy, France 54052 (Zannad)

Search for other papers by Faiez Zannad in
Current site
Google Scholar
PubMed
Close
 MD, PhD

Contributor Notes

Over the past 5 years, the following authors served as consultants or on advisory boards for and received support (at least 1 of speaker honoraria, remuneration of travel expenses, research funding, programmatic support [intern or resident funding or equipment]) from IDEXX Laboratories: Boswood, Fox, Gordon, Oyama, Rush, Stepien, and Wess. Dr. Ettinger received remuneration of travel expenses and programmatic support from IDEXX Laboratories. The remainder (Connolly, Sisson, Zannad) have no disclosures. IDEXX Laboratories did not have knowledge of or participate in formulating the idea to write the manuscript, in writing or review of the manuscript, or in the decision to submit the manuscript for publication.

Address correspondence to Dr. Oyama (maoyama@vet.upenn.edu).